Clinical Trial Detail

NCT ID NCT02922764
Title A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Rgenix, Inc.
Indications

lymphoma

ovary epithelial cancer

fallopian tube carcinoma

Advanced Solid Tumor

lung small cell carcinoma

peritoneal carcinoma

lung non-small cell carcinoma

Therapies

RGX-104

Ipilimumab + RGX-104

Nivolumab + RGX-104

Carboplatin + Pembrolizumab + Pemetrexed Disodium + RGX-104

Age Groups: senior adult

No variant requirements are available.